interferon alfa-2b | Viferon rectal suppositories 3,000,000 IU, 10 pcs.

Release form

Rectal suppositories.

Packing

10 pcs.

Pharmacological action

Interferon alfa-2b human recombinant has antiviral, immunomodulating, antiproliferative properties, inhibits the replication of RNA and DNA viruses. Immunomodulating properties of interferon alpha-2b, such as increased macrophage phagocytic activity, an increase in the specific cytotoxicity of lymphocytes to target cells determines its indirect antibacterial activity.

In the presence of ascorbic acid and alpha-tocopherol acetate, the specific antiviral activity of interferon alpha-2b increases, its immunomodulatory effect is enhanced, which allows to increase the efficiency of the body's own immune response to pathogenic microorganisms. When using the drug, the level of secretory immunoglobulins of class A increases, the level of immunoglobulin E is normalized, the functioning of the endogenous system of interferon alpha-2b is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and also regenerating properties. Established that when using VIFERON®, there are no side effects that occur during parenteral administration of interferon alpha-2b preparations, antibodies are not formed that neutralize the antiviral activity of interferon alpha-2b. The use of VIFERON® as part of complex therapy allows to reduce therapeutic doses of antibacterial and hormonal drugs, as well as reduce the toxic effects of this therapy.

Cocoa butter contains phospholipids that prevent synthetic toxic emulsifiers from being used in production, and the presence of polyunsaturated fatty acids facilitates the administration and dissolution of the drug.

Indications

- acute respiratory viral infections, including influenza, including complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of the complex therapy

- infectious and inflammatory diseases of newborns, including premature infants: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of

complex therapy - chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including in combination with plasmapheresis and hemosorption in case of severe viral hepatitis, complicated by liver cirrhosis

- infectious and inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults,

combination therapy includes a primary or recurrent herpetic infection of the skin and mucous membranes, a localized form, a mild and moderate course, including an urogenital form in adults.

Contraindications

Hypersensitivity to the components of the drug.

Use during pregnancy and lactation

Viferon is approved for use from the 14th week of pregnancy. It has no restrictions on the use during lactation.

Special instructions

For the treatment of a wide range of infectious and inflammatory diseases Viferon can be used as part of combination therapy with antibacterial drugs, glucocorticoids, immunosuppressive drugs.

There is evidence of the effectiveness of the use of Viferon as part of complex therapy and for the prevention of the following diseases and conditions: herpetic infections, chlamydia, ureaplasmosis, toxoplasmosis, cytomegalovirus infection in adults and children over 1 year old, viral hepatitis in adults, SARS, influenza, bronchial asthma, juvenile rheumatoid arthritis meningeal form of tick-borne encephalitis prostatitis of various etiologies purulent-septic postoperative complications, virus-associated glomerulonephritis, pyelonephus rits.

Composition

1 suppository VIFERONΠ3000000 ME contains active substance: human interferon alfa-2b recombinant 3000000 IU Excipients: ascorbic acid 0.0081 g, 0.0162 g of sodium ascorbate, alpha-tocopherol acetate 0.055 g, disodium edetate dihydrate 0.0001 g Polysorbate 80 0.0001 g, 0.1941 g of cocoa butter, confectionery fat or cocoa butter substitute up to 1 g.

Side effects

In rare cases, the development of allergic reactions (skin rashes, itching) is possible. These phenomena are reversible and disappear after 72 hours after stopping the drug.

Drug interaction

VIFERON®, rectal suppositories, is compatible and well combined with all drugs used in the treatment of the above diseases (antibiotics, chemotherapy, glucocorticosteroids).

Storage Conditions

The product should be stored in a dry, dark place at 2 ° to 8 РC.

Expiration

2 years.

Terms leave through pharmacies

without prescription

lekarstvennaja form

suppozytoryy rektaln e

Indications

Vaginal candidiasis, Hepatitis, Influenza, Chlamydia, Infection and urinary tract infections, vaginal infections, herpes, HPV

Possible product names

Viferon 3000000 IU Supp. rect. X10 (R)

Viferon rectal suppositories 3,000,000 IU, 10 pcs.

Viferon rectal suppositories 3,000,000 IU, 10 pcs.

Viferon supp rect 3mln ME N10

VIFERON SUPP. RECT. 3 MILLION ME No. 10

Fearon, Russia